Bank of New York Mellon Corp Boosts Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Bank of New York Mellon Corp increased its position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 23.1% in the fourth quarter, HoldingsChannel reports. The firm owned 71,300 shares of the company’s stock after purchasing an additional 13,372 shares during the quarter. Bank of New York Mellon Corp’s holdings in Werewolf Therapeutics were worth $106,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Werewolf Therapeutics by 6.3% in the third quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after purchasing an additional 40,692 shares in the last quarter. State Street Corp boosted its holdings in shares of Werewolf Therapeutics by 12.4% during the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after buying an additional 52,528 shares in the last quarter. Walleye Capital LLC grew its position in shares of Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares during the period. Barclays PLC increased its stake in shares of Werewolf Therapeutics by 130.1% in the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after acquiring an additional 30,990 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Werewolf Therapeutics during the 3rd quarter valued at about $45,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HOWL. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th. Finally, JMP Securities reduced their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $1.03 on Monday. The stock has a market cap of $46.17 million, a price-to-earnings ratio of -0.67 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics, Inc. has a 1 year low of $1.00 and a 1 year high of $6.89. The firm’s 50-day moving average is $1.29 and its 200 day moving average is $1.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%. Sell-side analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.